Patents Assigned to The Trustees of the University of Pennsylvania
-
Publication number: 20240082361Abstract: This invention relates to methods of treating and ameliorating congenital and neonatal hyperinsulinism and post-prandial hypoglycemia, comprising the step of administering an antagonist of the Glucagon-Like Peptide-1 (GLP-1) receptor, e.g. a GLP-1 fragment or analogue thereof.Type: ApplicationFiled: February 14, 2023Publication date: March 14, 2024Applicants: THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA, The Children's Hospital of PhiladelphiaInventors: Doris STOFFERS, Diva D. DE LEON, Charles STANLEY
-
Patent number: 11925466Abstract: An electrode, the electrode including an exposed contact surface, the exposed surface comprising a contact material, the contact material comprising a MXene. A device, the device including a plurality of electrodes, each of the plurality of electrodes comprising an exposed contact surface, the exposed surface comprising a contact material, the contact material comprising a MXene. A method, the method including delivering electrical stimulation to a subject with an electrode that comprises an exposed contact surface, the exposed contact surface comprising a contact material that includes a MXene.Type: GrantFiled: September 14, 2018Date of Patent: March 12, 2024Assignees: The Trustees of the University of Pennsylvania, Drexel UniversityInventors: Flavia Vitale, Brian Litt, Nicolette Driscoll, Yury Gogotsi, Babak Anasori, Kathleen Maleski
-
Patent number: 11925685Abstract: Disclosed herein is a composition comprising a recombinant nucleic acid sequence that encodes an antibody to a Zika viral antigen, and functional fragments thereof. The invention also relates to a composition comprising the combination of a first composition that elicits an immune response in a mammal against zika virus and a second composition comprising a recombinant nucleic acid sequence encoding an antibody, a fragment thereof, a variant thereof, or a combination thereof. In some instances, the nucleic acid molecule comprises a nucleotide sequence encoding an anti-ZIKV-Envelope (anti-ZIKV E) Protein antibody.Type: GrantFiled: September 19, 2017Date of Patent: March 12, 2024Assignees: The Trustees of the University of Pennsylvania, Inovio Pharmaceuticals, Inc., The Wistar Institute of Anatomy and BiologyInventors: David Weiner, Karuppiah Muthumani, Jian Yan
-
Patent number: 11925662Abstract: The present invention relates to compositions and methods that provide novel anti-tumor therapies in cancer. In one aspect, the present invention features a hybrid neutrophil in a non-naturally occurring container, wherein the hybrid neutrophil expresses at least one neutrophil associated molecule selected from the group consisting of: Arg1, MPO, CD66b, and CD15, and at least one antigen-presenting cell (APC) associated molecule selected from the group consisting of: CD14, HLA-DR, CD32, CD64, and CD89. In another aspect, the present invention features methods of generating a hybrid neutrophil. In still another aspect, the present invention features methods of inhibiting tumor growth in a subject, treating a tumor in a subject, and increasing efficacy of an antibody against a tumor in a subject. The methods comprise (a) administering to the subject an effective amount of an anti-tumor antibody and (b) administering to or generating in the subject an effective amount of a hybrid neutrophil.Type: GrantFiled: December 15, 2020Date of Patent: March 12, 2024Assignee: The Trustees of the University of PennsylvaniaInventors: Evgeniy Eruslanov, Steven Albelda
-
Patent number: 11918586Abstract: The present invention is relates to a compound of formula (I), wherein X1, X2 and X3 are, independently of each other, N or CH; with the proviso that at least two of X1 X2 and X3 are N; Y is N or CH; W is H or F; with the proviso that when W is F, then X1, X2 and X3 are N; R1 and R2 are independently of each other (i) a morpholinyl of formula (II) wherein the arrow denotes the bond in formula (I); and wherein R3 and R4 are independently of each other H, C1-C3alkyl optionally substituted with one or two OH, C1-C2fluoroalkyl, C1-C2alkoxy, C1alkoxyC1-C3alkyl, CN, or C(O)O—C1-C2alkyl; or R3 and R4 form together a bivalent residue —R5R6— selected from C1-C3alkylene optionally substituted with 1 to 4 F, —CH2—O—CH2—, —CH2—NH—CH2—, or any of the structures wherein the arrows denote the bonds in formula (II); or (ii) a saturated 6-membered heterocyclic ring Z selected from thiomorpholinyl and piperazinyl, optionally substituted by 1 to 3 R7; wherein R7 is independently at each occurrence C1-C3alkyl optionally substituType: GrantFiled: March 26, 2021Date of Patent: March 5, 2024Assignees: TORQUR AG, THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIAInventors: Doriano Fabbro, Paul Hebeisen, Petra Hillmann-Wuellner, Anton Stuetz, John T. Seykora, Florent Beaufils
-
Patent number: 11919946Abstract: The present invention provides compositions and methods for regulating the specificity and activity of T cells. In one embodiment, the invention provides a type of chimeric antigen receptor (CAR) wherein the CAR is termed a “KIR-CAR” which is a CAR design comprising a component of a receptor naturally found on natural killer (NK) cells. In one embodiment, the NK receptor includes but is not limited to a naturally occurring activating and inhibitory receptor of NK cells known as a killer cell immunoglobulin-like receptor (KIR).Type: GrantFiled: April 1, 2020Date of Patent: March 5, 2024Assignees: Novartis AG, The Trustees of the University of PennsylvaniaInventors: Michael C. Milone, Enxiu Wang
-
Patent number: 11920130Abstract: The present disclosure provides gene edited modified immune cells or precursors thereof (e.g., gene edited modified T cells) comprising an exogenous T cell receptor (TCR) and/or a chimeric antigen receptor (CAR) having specificity for a target antigen, and an insertion and/or deletion in one or more endogenous gene loci, wherein the endogenous gene loci encode regulators of T cell function, thereby resulting in immune cells having enhanced function. Compositions and methods of treatment are also provided. The present invention provides methods of screening for TCR- or CAR-T cells with enhanced immune function (e.g., T cell efficacy, T cell memory, and/or T cell persistence).Type: GrantFiled: May 12, 2022Date of Patent: March 5, 2024Assignee: The Trustees of the University of PennsylvaniaInventors: Yangbing Zhao, Jiangtao Ren
-
Patent number: 11920116Abstract: The presently disclosed subject matter provides systems and methods for producing a three-dimensional model of a human cervix. A microdevice is provided for culturing human cervical cells. The microdevice can include an upper microchannel including live ectocervical epithelial cells. The microdevice can include a lower microchannel including a first parallel lane and a second parallel lane including stromal media. The first and the second parallel lanes can be lined with live vascular endothelial cells. The lower microchannel can include a third parallel lane including uterine fibroblasts and live smooth muscle cells embedded in hydrogel. The first, second, and third lanes of the lower microchannel can be separated by protrusion structures. The third parallel lane can be positioned in the lower microchannel in between the first and the second parallel lanes. The microdevice can further include a porous membrane positioned in between the upper microchannel and the lower microchannel.Type: GrantFiled: June 18, 2021Date of Patent: March 5, 2024Assignee: The Trustees of the University of PennsylvaniaInventors: Dongeun Huh, Jeongyun Seo
-
Patent number: 11923908Abstract: Provided are methods for optical communication, comprising: generating a phase difference signal with heterodyne or homodyne phase-locked-loop (PLL) from between an optical input signal and a local laser source; controlling the local laser source with the phase difference signal; demodulating the optical input signal using the local laser source as a carrier signal to generate a baseband output signal; and controlling the heterodyne or homodyne PLL and the demodulation with an electrical oscillator signal. Also provided are related methods.Type: GrantFiled: March 18, 2022Date of Patent: March 5, 2024Assignee: The Trustees of the University of PennsylvaniaInventors: Firooz Aflatouni, Zhe Xuan
-
Publication number: 20240067948Abstract: The present invention includes mutant AID, APOBEC, and Tet enzymes with improved functions. In one aspect the invention provides APOBEC fusion proteins comprising hyperactive deamination activity. In another aspect, the invention provides AID mutant proteins comprising hyperactive deamination activity. In yet another aspect, the invention provides mutant Tet proteins capable of stalling oxidation at a 5-hydroxymethylcytosine (hmC).Type: ApplicationFiled: April 5, 2023Publication date: February 29, 2024Applicant: THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIAInventors: Rahul Kohli, Emily Schutsky, Monica Yun Liu
-
Patent number: 11913026Abstract: A bispecific cytotoxic lymphocyte or macrophage-redirecting autoantibody comprising a cytotoxic lymphocyte or macrophage targeting domain and an autoantibody. Methods for producing bispecific cytotoxic lymphocyte or macrophage-redirecting autoantibody comprising a cytotoxic lymphocyte or macrophage targeting domain and an autoantibody. Methods for treating a subject in need thereof comprising administering to the subject an isolated bispecific cytotoxic lymphocyte or macrophage-redirecting autoantibody.Type: GrantFiled: March 17, 2020Date of Patent: February 27, 2024Assignee: THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIAInventors: Andrew Tsourkas, James Z. Hui, Burcin Altun, Fabiana Zappala
-
Patent number: 11913963Abstract: The present invention provides a humanized antibody or antibody fragment comprising (a) a humanized light chain comprising 1) Complementarity Determining Region (CDR)-L1, the sequence of which is identical to the sequence of SEQ ID NO: 3; 2) CDR-L2, the sequence of which is identical to the sequence of SEQ ID NO: 4; and 3) CDR-L3, the sequence of which is identical to the sequence of SEQ ID NO: 5, and (b) a humanized heavy chain comprising 1) CDR-H1, the sequence of which is identical to the sequence of SEQ ID NO: 6; 2) CDR-H2, the sequence of which is identical to the sequence of SEQ ID NO: 7; and 3) CDR-H3, the sequence of which is identical to the sequence of SEQ ID NO: 8, as well as methods for treating, diagnosing, and monitoring the progression of HIT. The present invention also provides methods for assessing the antigenicity and ability to cause HIT of anionic anticoagulants.Type: GrantFiled: September 2, 2022Date of Patent: February 27, 2024Assignee: The Trustees of the University of PennsylvaniaInventors: Mark I. Greene, Douglas B. Cines, Zheng Cai, Zhiqiang Zhu
-
Patent number: 11912753Abstract: The invention provides compositions and methods for adoptive T cell therapy in treating a variety of disorders including cancer, infections, and autoimmune disorders. In one embodiment, the invention provides a universal immune receptor (UnivIR) that comprises an extracellular label binding domain, a transmembrane domain, and a cytoplasmic domain or otherwise an intracellular domain.Type: GrantFiled: June 21, 2021Date of Patent: February 27, 2024Assignee: The Trustees of the University of PennsylvaniaInventors: Nathalie Scholler, Katarzyna Urbanska, Daniel J. Powell, Jr.
-
Patent number: 11905321Abstract: The invention includes a chimeric autoantibody receptor (CAAR) specific for anti-muscle-specific kinase (MuSK) B cell receptor (BCR), compositions comprising the CAAR, polynucleotides encoding the CAAR, vectors comprising a polynucleotide encoding the CAAR, and recombinant cells comprising the CAAR.Type: GrantFiled: June 4, 2019Date of Patent: February 20, 2024Assignee: The Trustees of the University of PennsylvaniaInventors: Aimee S. Payne, Christoph T. Ellebrecht, Sangwook Oh, Michael C. Milone
-
Patent number: 11903929Abstract: The present invention concerns the use of compounds and compositions for the treatment or prevention of Flavivirus infections, such as dengue virus infections and Zika virus infections. Aspects of the invention include methods for treating or preventing Flavivirus virus infection, such as dengue virus and Zika virus infection, by administering a compound or composition of the invention, to a subject in need thereof; methods for inhibiting Flavivirus infections, such as dengue virus and Zika virus infections, in a cell in vitro or in vivo; pharmaceutical compositions; packaged dosage formulations; and kits useful for treating or preventing Flavivirus infections, such as dengue virus and Zika virus infections.Type: GrantFiled: June 28, 2022Date of Patent: February 20, 2024Assignees: Florida State University Research Foundation, Inc., The Unites States of America, as represented by the Secretary Department of Health and Human Services, The Trustees of the University of PennsylvaniaInventors: Hengli Tang, Emily M. Lee, Wei Zheng, Ruili Huang, Miao Xu, Wenwei Huang, Khalida Shamim, Guoli Ming, Hongjun Song
-
Patent number: 11906511Abstract: The present invention provides compositions and methods for detecting exhausted T cells in a subject. The present invention also provides methods for treating a subject having a disease characterized by the presence of exhausted T cells or certain subpopulations thereof.Type: GrantFiled: October 26, 2018Date of Patent: February 20, 2024Assignee: The Trustees of the University of PennsylvaniaInventors: E. John Wherry, Bertram Bengsch, Omar Khan, Jennifer Wu, Josephine Giles
-
Publication number: 20240050186Abstract: Devices and methods for stereotactic placement of a catheter are disclosed herein. The device can include a conical component comprising a first opening and a second opening, a cylindrical rod for receiving the catheter, a footplate for securing the device underneath a skin of a subject, and a clip for holding the catheter. The first opening and second opening can form a lumen therethrough. The cylindrical rod can be coupled to the first opening, and the footplate can be coupled to the conical component.Type: ApplicationFiled: October 26, 2023Publication date: February 15, 2024Applicant: THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIAInventors: Rachel BLUE, Michael SPADOLA
-
Patent number: 11897845Abstract: Provided is a compound of formula (I) in which Ar1, R1, U, V, W, X, and p are as described herein. Also provided are methods of using a compound of formula (I), including a method of treating cancer, a method of treating a patient with cancer cells resistant to an anti-cancer agent, and a method of inhibiting lactate dehydrogenase A (LDHA) and/or lactate dehydrogenase B (LDHB) activity in a cell.Type: GrantFiled: January 10, 2022Date of Patent: February 13, 2024Assignees: THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES, VANDERBILT UNIVERSITY, THE UAB RESEARCH FOUNDATION, THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIAInventors: David J. Maloney, Alex Gregory Waterson, Ganesh Rai Bantukallu, Kyle Ryan Brimacombe, Plamen Christov, Chi V. Dang, Victor Darley-Usmar, Xin Hu, Ajit Jadhav, Somnath Jana, Kwangho Kim, Jennifer L. Kouznetsova, William J. Moore, Bryan T. Mott, Leonard M. Neckers, Anton Simeonov, Gary Allen Sulikowski, Daniel Jason Urban, Shyh Ming Yang
-
Patent number: 11896654Abstract: Disclosed herein is a composition including a recombinant nucleic acid sequence that encodes an antibody or fragment thereof that targets an immune checkpoint molecule. The disclosure also provides a method of preventing and/or treating disease in a subject using said composition and method of generation.Type: GrantFiled: May 5, 2017Date of Patent: February 13, 2024Assignees: The Trustees of the University of Pennsylvania, The Wistar Institute of Anatomy and Biology, Inovio PharmaceuticalsInventors: David B. Weiner, Kar Muthumani, Niranjan Sardesai
-
Patent number: RE49847Abstract: The invention provides compositions and methods for treating diseases associated with expression of CD20 or CD22. The invention also relates to chimeric antigen receptor (CAR) specific to CD20 or CD22, vectors encoding the same, and recombinant T or natural killer (NK) cells comprising the CD20 CAR or CD22 CAR. The invention also includes methods of administering a genetically modified T cell or NK cell expressing a CAR that comprises a CD20 or CD22 binding domain.Type: GrantFiled: January 5, 2022Date of Patent: February 27, 2024Assignees: Novartis AG, The Trustees of the University of PennsylvaniaInventors: Barbara Brannetti, Jennifer Brogdon, Boris Engels, Brian Granda, Lu Huang, Ming Lei, Na Li, Jimin Zhang, Carla Guimaraes, Saar Gill, Marco Ruella, Regina M. Young